Penrose TherapeuTx Revenue and Competitors
Estimated Revenue & Valuation
- Penrose TherapeuTx's estimated annual revenue is currently $2.4M per year.
- Penrose TherapeuTx's estimated revenue per employee is $201,000
Employee Data
- Penrose TherapeuTx has 12 Employees.
- Penrose TherapeuTx grew their employee count by 0% last year.
Penrose TherapeuTx's People
Name | Title | Email/Phone |
---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | VP Operations | Reveal Email/Phone |
4 | Research Scientist I | Reveal Email/Phone |
5 | Principal Scientist, Analytical Chemistry | Reveal Email/Phone |
6 | Scientist | Reveal Email/Phone |
Penrose TherapeuTx Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $67.1M | 267 | 6% | $10.8M | N/A |
#2 | $7.8M | 39 | 8% | N/A | N/A |
#3 | $5M | 25 | 4% | N/A | N/A |
#4 | $12.7M | 63 | -6% | N/A | N/A |
#5 | $16.5M | 82 | -4% | N/A | N/A |
#6 | $59.5M | 296 | 7% | N/A | N/A |
#7 | $96.2M | 342 | 29% | $764.2M | N/A |
#8 | $6.8M | 34 | 10% | N/A | N/A |
#9 | $5.4M | 27 | -4% | N/A | N/A |
#10 | $8.2M | 41 | 5% | N/A | N/A |
What Is Penrose TherapeuTx?
Penrose TherapeuTx is a U.S.-based pharmaceutical company focused on developing innovative small-molecule therapies for the treatment of advanced cancers. Penrose has pioneered the development of a novel Mitochondrial Modifying Agent (MMA) therapeutic platform designed to generate therapies for difficult to treat cancers through a unique cooperative mechanism of action. Our approach has potential broad applicability across both hematologic and solid tumors.
keywords:N/AN/A
Total Funding
12
Number of Employees
$2.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.9M | 12 | 0% | N/A |
#2 | $35M | 12 | 50% | N/A |
#3 | $1M | 12 | 9% | N/A |
#4 | $1.4M | 12 | N/A | N/A |
#5 | $1.6M | 13 | -7% | N/A |